Candel Therapeutics (CADL) news
Recent news
Candel Therapeutics Inc: Stifel initiates coverage with buy rating; target price $22
Stifel has initiated coverage on Candel Therapeutics Inc. (NASDAQ:CADL) with a Buy rating and a price target of $22.00, representing upside from the stock's price of $9.49 as of July 13, 2026. The firm highlighted the biotech's aglatimagene besadenovec, a locally administered viral immunotherapy…
AInvest Wire · Jul 13, 2026Candel Therapeutics announces inducement grant under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Jul 8, 2026Candel Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Jul 1, 2026Candel Therapeutics appoints Mark Sims as chief commercial officer
AInvest Wire · Jun 25, 2026ImportantCandel Therapeutics announces FDA fast track designation for CAN-2409
Candel Therapeutics announces FDA fast track designation for CAN-2409 More Info: Candel Therapeutics, a clinical-stage biopharmaceutical company, recently announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for its lead asset, CAN-2409, an investigational…
AInvest Wire · Dec 12, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.